5 questions about the FDA’s fast-track push for psychedelic treatments

5 questions about the FDA’s fast-track push for psychedelic treatments

Summary

The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two...

Description

The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage